FDA staff tested Elsa on Monday with questions about FDA-approved products or other public information, only to find that it provided summaries that were either completely or partially wrong.

The U.S. Food and Drug Administration (FDA) has launched Elsa, an AI tool designed to modernize and speed up agency-wide operations ranging from scientific reviews to investigations. Marty Makary ...

The FDA’s tool—nicknamed Elsa—is designed to assist employees with everything from scientific reviews to basic operations. Originally, the FDA planned to launch by June 30, ...

The launch of Elsa represents the first step in the FDA’s broader adoption of AI technologies. The agency plans to expand the tool’s capabilities further, integrating AI into additional processes.

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. The FDA plans to roll out its new AI tool, called Elsa ...

The FDA launched an artificial intelligence tool Monday dubbed Elsa, with Commissioner Marty Makary hyping the effort’s early debut “to modernize how the agency functions.” ...

The FDA is using Elsa to accelerate clinical protocol reviews, shorten the time needed for scientific evaluations and identify high-priority inspection targets. The Food and Drug Administration ...

Elsa’s deployment comes ahead of schedule, with the rollout date initially slated for June 30. Leadership at the FDA has been keen to incorporate more AI tools across agency operations following ...

The FDA launched a generative artificial intelligence (AI) tool, dubbed Elsa, designed to help employees such as scientific reviewers and investigators work more efficiently, the agency announced ...

In this edition of STAT's AI Prognosis: FDA's AI tool, Elsa was launched across the agency weeks ahead of shcedule, and more health AI news.